SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
SLS

SELLAS Life Sciences Group, Inc (NASDAQ:SLS)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$8.58+$0.16 (+1.90%)
 
Market cap
$1.73B
Insider Score
Health Score
Analyst consensus
Listed since
Mar 12, 2008
Market Cap$1.73B+472.0%
Revenue (ttm)$0
Net Income-$32.46M-23.6%
EPS-$0.21+35.4%
Shares Out201.95M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,762,805
Open$8.16
Previous Close$8.42
Day's Range$7.89 - $8.87
52-Week Range$1.39 - $15.88
Beta2.70
AnalystsBuy
Price Target$35.00(+307.93%)
Earnings DateNov 18, 2026

About SLS

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009; and Memorial Sloan Kettering Cancer Center for developing and commercializing MSK's WT1 peptide vaccine technology. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Address
7 Times Square, New York, NY, 10036, US
Market Cap
1.73 billion
Employees
13
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$0
Bought
$149.41K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Fair
From SLS’s reported statements · Q2 2026 (trailing 12 months) · 4 of 5 pillars
1 Day
+1.90%
5 Days
-4.77%
1 Month
-26.35%
6 Months
+71.26%
1 Year
+472.00%

$SLS stock is featured in our Insider Trades datasets.

→ All Stock Lists

Recently reported changes in SLS holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by SLS's directors and management

Net Shares Purchased by Insiders−70k−35k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

SLS Estimated quarterly lobbying spending

Source: U.S. Senate LDA

SLS Revenue by Segment

$404.00MTotal
Future milestone payments received$194.50M48.14%
Potential milestone payments to be received$191.50M47.40%
Licensing revenue$10.50M2.60%
Upfront cash payment received$7.50M1.86%

As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New SLS patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to SLS from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in SLS

XBIState Street SPDR S&P Biotech ETF$49.50M
IWMiShares Russell 2000 ETF$43.89M
VXFVanguard Extended Market ETF$28.06M
IWOiShares Russell 2000 Growth ETF$16.06M
VTWOVanguard Russell 2000 ETF$14.39M
SCHASchwab U.S. Small-Cap ETF$9.08M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from SLS’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
No data yet
—
Analyst Ratings
62% of score
99
News & Sentiment
38% of score
68

News check: Positive Phase 2 AML data and upcoming Q4 results drive optimism, though stock volatility and analyst stake cuts create mixed near-term signals.

Recent Insider Activity

Buys
3
Sells
0
Buy Value
$149.41K
Distinct Buyers
3

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

SBIOALPS Medical Breakthroughs ETF1.06%
BBCVirtus Biotech Clinical Trials ETF0.79%
ETHOAmplify Etho Climate Leadership U.S. ETF0.56%
XBIState Street SPDR S&P Biotech ETF0.46%
IWCiShares Micro-Cap ETF0.42%
AFSMFirst Trust Active Factor Small Cap ETF0.32%
VFMOVanguard U.S. Momentum Factor ETF0.19%
VTWGVanguard Russell 2000 Growth ETF0.16%
VMO.TOVanguard Global Momentum Factor ETF0.15%
IWOiShares Russell 2000 Growth ETF0.11%
USVMVictoryShares US Small Mid Cap Value Momentum ETF0.10%
PWSPacer WealthShield ETF0.09%

Weight is the stock’s share of each fund’s holdings.